Betsy Goodfellow
Pharmafile
July 23, 2024
ViroCell Biologics has announced that it has signed a five-year Master Services Agreement (MSA) with a prominent US-based NCI-designated cancer centre.
Under the terms of this agreement, the cancer centre will be able to access ViroCell’s complete range of pre-clinical and clinical viral vector services in order to accelerate its clinical development of novel gene-modified cell therapies.
According to the press release, the pre-clinical services include ‘viral vector design, MicroBatch and pre-clinical batch manufacturing and process development’, while the clinical services include ‘global plasmid sourcing, GMP manufacturing, expedited quality control release testing, regulatory filing support, and in-house Qualified Person (QP) batch review and approval for export and use in global clinical trials’.
John W Hadden II, chief executive officer at ViroCell Biologics, commented: “We are delighted to have signed this Master Services Agreement with one of the world’s premier cancer research centres. It further underscores our ability to provide highly specialised GMP viral vector manufacturing services to cutting-edge research groups both in academia and industry as they translate their science into next-generation cell and gene therapies. We look forward to working closely with the scientists at this prestigious institution, as they commence exciting new cancer drug development programmes.”